CALiBRe looks at the mechanism of action of idelalisib. Idelalisib has been tested previously in clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL) patients, but the way it works is still unknown. CALiBRe will also investigate how idelalisib affects the rate of growth, and the lifespan, of leukaemia cells in patients with CLL.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
Chief Investigator:
|
Peter Hillmen |
| Sponsor: |
University of Birmingham |
| Funders: |
TAP Bloodwise |
Disease Site:
|
Chronic Lymphocytic Leukaemia |
Trial Type:
|
Clinical Trial of an Investigational Medicinal Product |
Status:
|
OPEN |
UKCRN Study ID:
|
18679 |
Open to new sites?
|
No |
Recruitment start date:
|
13 July 2015 |
| Anticipated Recruitment end date: |
31 Oct 2018 |
| CRCTU Trial Management Team: |
Haematology |
Trial E-mail Address:
|
CALiBRe@trials.bham.ac.uk |